Literature DB >> 8077946

Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles.

R C Rose1, W Bonnez, C Da Rin, D J McCance, R C Reichman.   

Abstract

The L1 major capsid protein-coding sequences of human papillomavirus (HPV) types 11, 16 and 18 were expressed in the baculovirus system. Virus-like particles (VLPs) were purified from recombinant-infected Spodoptera frugiperda Sf9 cells and cell-free culture supernatants. Rabbits immunized with purified VLPs developed antibodies that reacted only with the specific VLP type used as the immunogen. In addition, rabbit antibodies raised against infectious HPV-11 virions only reacted with HPV-11 L1 VLPs and not with VLPs derived from either HPV-16 or HPV-18. These results suggest that HPV-11, HPV-16 and HPV-18 virions are antigenically distinct from one another. This observation should be considered in future studies of immune responses to HPV.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8077946     DOI: 10.1099/0022-1317-75-9-2445

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  33 in total

1.  Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.

Authors:  R B Roden; A Armstrong; P Haderer; N D Christensen; N L Hubbert; D R Lowy; J T Schiller; R Kirnbauer
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  A quadrivalent HPV vaccine induces humoral and cellular immune responses in WHIM immunodeficiency syndrome.

Authors:  Alessandra Handisurya; Christina Schellenbacher; Bärbel Reininger; Frieder Koszik; Philipp Vyhnanek; Andreas Heitger; Reinhard Kirnbauer; Elisabeth Förster-Waldl
Journal:  Vaccine       Date:  2010-05-14       Impact factor: 3.641

3.  Characterization of an IL-12 p40/p35 Truncated Fusion Protein That can Inhibit the Action of IL-12.

Authors:  Denise Skrombolas; Isabel Wylie; Shivana Maharaj; John G Frelinger
Journal:  J Interferon Cytokine Res       Date:  2015-05-04       Impact factor: 2.607

4.  Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.

Authors:  Ratish Gambhira; Subhashini Jagu; Balasubramanyam Karanam; Patti E Gravitt; Timothy D Culp; Neil D Christensen; Richard B S Roden
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

5.  Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies.

Authors:  R C Rose; W I White; M Li; J A Suzich; C Lane; R L Garcea
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

6.  Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein.

Authors:  Monica E Embers; Lynn R Budgeon; Martin Pickel; Neil D Christensen
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts.

Authors:  C E Greer; C M Wheeler; M B Ladner; K Beutner; M Y Coyne; H Liang; A Langenberg; T S Yen; R Ralston
Journal:  J Clin Microbiol       Date:  1995-08       Impact factor: 5.948

8.  Induction of immune responses against human papillomaviruses by hypervariable epitope constructs.

Authors:  K Jyotsna Reddy; Babak Banapour; David E Anderson; Sang H Lee; Juan P Marquez; Maria P Carlos; Jose V Torres
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

9.  Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres.

Authors:  Yoshihiko Murata; Paula M Lightfoote; Robert C Rose; Edward E Walsh
Journal:  Virol J       Date:  2009-06-18       Impact factor: 4.099

10.  Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.

Authors:  Subhashini Jagu; Balasubramanyam Karanam; Ratish Gambhira; Sudha V Chivukula; Revathi J Chaganti; Douglas R Lowy; John T Schiller; Richard B S Roden
Journal:  J Natl Cancer Inst       Date:  2009-05-26       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.